Literature DB >> 11827571

Cytostatic properties of a novel compound derived from Penicillium pinophilum: an in vitro study.

Annalaura Stammati1, Rosario Nicoletti, Salvatore De Stefano, Franco Zampaglioni, Flavia Zucco.   

Abstract

3-O-Methylfunicone (OMF), a secondary metabolite produced by Penicillium pinophilum, inhibits the in vitro growth of plant pathogenic fungi. This specific property suggested that the compound could be used against other fungal pathogenic activities, including dermatological ones. However, for such applications, toxicological side-effects should be taken into account, in order to prevent other types of risk to mammalian cells. Therefore, investigations were made of the basic toxicity of OMF toward a human tumour cell line. The compound was found to have a cytostatic effect, which represents a counter-indication to its use as a therapeutic agent in dermatology, but suggests that it may have potential as an anti-tumour agent. This study confirmed the validity of in vitro systems for preliminary assays on new compounds, in order to avoid the use of animals in toxicological studies.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11827571     DOI: 10.1177/026119290203000107

Source DB:  PubMed          Journal:  Altern Lab Anim        ISSN: 0261-1929            Impact factor:   1.303


  10 in total

1.  3-O-methylfunicone, from Penicillium pinophilum, is a selective inhibitor of breast cancer stem cells.

Authors:  E Buommino; V Tirino; A De Filippis; F Silvestri; R Nicoletti; M L Ciavatta; G Pirozzi; M A Tufano
Journal:  Cell Prolif       Date:  2011-10       Impact factor: 6.831

2.  3-O-Methylfunicone, a metabolite produced by Penicillium pinophilum, modulates ERK1/2 activity, affecting cell motility of human mesothelioma cells.

Authors:  E Buommino; I Paoletti; A De Filippis; R Nicoletti; M L Ciavatta; S Menegozzo; M Menegozzo; M A Tufano
Journal:  Cell Prolif       Date:  2010-04       Impact factor: 6.831

3.  Antagonism against Rhizoctonia solani and fungitoxic metabolite production by some Penicillium isolates.

Authors:  R Nicoletti; M De Stefano; S De Stefano; A Trincone; F Marziano
Journal:  Mycopathologia       Date:  2004-11       Impact factor: 2.574

4.  3-O-methylfunicone, a metabolite of Penicillium pinophilum, inhibits proliferation of human melanoma cells by causing G(2) + M arrest and inducing apoptosis.

Authors:  A Baroni; A De Luca; A De Filippis; M Petrazzuolo; L Manente; R Nicoletti; M A Tufano; E Buommino
Journal:  Cell Prolif       Date:  2009-05-22       Impact factor: 6.831

5.  3-O-methylfunicone, a secondary metabolite produced by Penicillium pinophilum, induces growth arrest and apoptosis in HeLa cells.

Authors:  E Buommino; R Nicoletti; G M Gaeta; M Orlando; M L Ciavatta; A Baroni; M A Tufano
Journal:  Cell Prolif       Date:  2004-12       Impact factor: 6.831

Review 6.  Bioactive Compounds Produced by Strains of Penicillium and Talaromyces of Marine Origin.

Authors:  Rosario Nicoletti; Antonio Trincone
Journal:  Mar Drugs       Date:  2016-02-18       Impact factor: 5.118

Review 7.  New Insights into Chemical and Biological Properties of Funicone-like Compounds.

Authors:  Maria Michela Salvatore; Marina DellaGreca; Anna Andolfi; Rosario Nicoletti
Journal:  Toxins (Basel)       Date:  2022-07-08       Impact factor: 5.075

8.  Production and fungitoxic activity of Sch 642305, a secondary metabolite of Penicillium canescens.

Authors:  Rosario Nicoletti; Maria Pilar Lopez-Gresa; Emiliano Manzo; Angela Carella; Maria Letizia Ciavatta
Journal:  Mycopathologia       Date:  2007-04-12       Impact factor: 3.785

Review 9.  Occurence and bioactivities of funicone-related compounds.

Authors:  Rosario Nicoletti; Emiliano Manzo; Maria Letizia Ciavatta
Journal:  Int J Mol Sci       Date:  2009-03-30       Impact factor: 6.208

Review 10.  Anticancer and antifungal compounds from Aspergillus, Penicillium and other filamentous fungi.

Authors:  Tanja Thorskov Bladt; Jens Christian Frisvad; Peter Boldsen Knudsen; Thomas Ostenfeld Larsen
Journal:  Molecules       Date:  2013-09-13       Impact factor: 4.411

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.